Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Ann. hepatol ; 16(1): 71-76, Jan.-Feb. 2017. graf
Article in English | LILACS | ID: biblio-838088

ABSTRACT

Abstract: Background. Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. Aim. To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients. Material and methods. Sixty-one patients with HCV genotype 1b were enrolled in the Turkish early access program. Most of the patients were in difficult-to-treat category. Patients were visited at each 4 week throughout the follow-up period. Laboratory findings and adverse events were recorded at each visit. Results. Fifty-seven of 61 enrolled patients completed 24 weeks of treatment. Two patients died as a result of underlying diseases at 12-14th weeks of treatment. Two patients stopped the treatment early as a consequence of virological breakthrough, and 2 patients had viral relapse at the post-treatment follow-up. Overall SVR12 rates were 90% (55/61) and 93.2% (55/59) according to intention-to-treat (ITT) and per protocol (PP) analysis respectively. In ITT analysis, SVR12 was achieved by 93% (13/14) in relapsers, 80% (12/15) in interferon-ineligible patients and 91% (20/22) in previous nonresponder patients. SVR12 rates were 86.5% and 91.4% in patients with cirrhosis according to ITT and PP analysis respectively. SVR12 was 95.8% in non-cirrhosis group in both analysis. Patients with previous protease inhibitor experience had an SVR12 of 87.5%. Common adverse events developed in 28.8% of patients. There were no treatment related severe adverse event or grade-4 laboratory abnormality. Conclusions. Daclatasvir and asunaprevir dual therapy is found to be effective and safe in difficult-to-treat Turkish patients with HCV genotype 1b infection.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Antiviral Agents/therapeutic use , Sulfonamides/therapeutic use , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Health Services Accessibility , Imidazoles/therapeutic use , Isoquinolines/therapeutic use , Antiviral Agents/economics , Antiviral Agents/adverse effects , Sulfonamides/economics , Sulfonamides/adverse effects , Time Factors , Turkey , RNA, Viral/genetics , Program Evaluation , Treatment Outcome , Drug Costs , Cost-Benefit Analysis , Hepacivirus/genetics , Viral Load , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/economics , Hepatitis C, Chronic/virology , Drug Therapy, Combination , Genotype , Health Services Accessibility/economics , Imidazoles/economics , Imidazoles/adverse effects , Isoquinolines/economics , Isoquinolines/adverse effects
2.
Arq. gastroenterol ; 52(1): 14-17, Jan-Mar/2015. graf
Article in English | LILACS | ID: lil-746485

ABSTRACT

Background Chronic hepatitis C has great impact on world’s health. Current therapy for genotype 1 hepatitis C virus includes protease inhibitors boceprevir and telaprevir, associated to standard therapy - peginterferon alfa + ribavirin. There are no published data in Brazil on the results of this new therapy, and it is interesting an evaluation of what was accomplished up to this moment. Objectives To evaluate virologic response to triple therapy, as well as the safety profile and tolerability. Method This study is a clinical series of patients receiving triple therapy for C hepatitis in a single center of a Public Health System of South Brasil. Out of the 121 patients that initiated the triple therapy, the first patients that finished the treatment and evaluated the sustained virological response (24 weeks after the end of treatment) were included. Results Twenty four genotype 1 chronic hepatitis C monoinfected patients were included. Nineteen (79.2%) patients had been previously treated. Thirteen (54.2%) patients were cirrhotic. Nineteen (79.2%) patients completed the planned therapy. By the end of the treatment, 14 (58.3%) out of 24 patients had undetectable viral load. Sustained virologic response occurred in 12 (50.0%) out of 24 patients, 07 (58.3%) in telaprevir group and 05 (41.7%) in boceprevir group. Out of 24 patients under triple therapy, 58% (n=14) presented anemia. Conclusions In conclusion, despite the small number of patients treated with triple therapy evaluated in the current study, it possibly reflects the population under this therapy in real-life. .


Contexto A hepatite crônica pelo vírus C tem grande impacto na saúde mundial. A terapia atual do genótipo 1 inclui os inibidores de protease (IP) boceprevir e telaprevir, associados à terapia padrão - alfapeginterferona + ribavirina (PR). No Brasil ainda não há estudos publicados sobre os resultados dessa nova terapia, sendo de interesse uma avaliação do que foi realizado até o momento. Objetivos Avaliar a resposta virológica ao tratamento triplo, bem como o perfil de segurança e tolerabilidade. Métodos O estudo consta de série de casos dos pacientes em uso de terapia tripla para o tratamento da hepatite C em um polo de tratamento da Secretaria Estadual da Saúde do Estado do Rio Grande do Sul, Brasil. Dentre os 121 pacientes que estão em uso de terapia tripla (PR e IP) foram apresentados os dados referentes aos primeiros que finalizaram o tratamento e realizaram avaliação da resposta virológica sustentada na semana 24 pós-tratamento. Resultados Foram incluídos 24 pacientes monoinfectados por hepatite C crônica genótipo 1. Dezenove (79%) pacientes eram previamente experimentados. Treze (54,2%) pacientes apresentavam cirrose. Dezenove (79,2%) pacientes completaram o tratamento planejado. Ao final do tratamento, 14 (58,3%) dos 24 pacientes apresentaram carga viral indetectável. Resposta virológica sustentada ocorreu em 12 (50%) dos 24 pacientes, sendo 07 (58,3%) no grupo telaprevir e 05 (41,7%) no grupo boceprevir. Dos 24 pacientes submetidos à terapia tripla, 58% (n=14) apresentaram anemia. Conclusões Embora o presente estudo tenha avaliado um pequeno número de casos, possivelmente reflete a população submetida à terapia tripla na vida real, despida das restrições dos estudos de registro. .


Subject(s)
Female , Humans , Male , Middle Aged , Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Antiviral Agents/adverse effects , Brazil , Drug Therapy, Combination/methods , Interferon-alpha/adverse effects , Interferon-alpha/therapeutic use , National Health Programs , Oligopeptides/adverse effects , Oligopeptides/therapeutic use , Public Health , Retrospective Studies , Ribavirin/adverse effects , Ribavirin/therapeutic use , Viral Load
3.
RBM rev. bras. med ; 71(10)out. 2014.
Article in Portuguese | LILACS | ID: lil-737107

ABSTRACT

Introdução: O vírus da hepatite C tem como principal via de transmissão a parenteral. A biópsia hepática constitui poderosa ferramenta e tem como parâmetros o grau de alteração estrutural e atividade inflamatória, permitindo estadiar as hepatites crônicas. Sendo a biópsia procedimento invasivo, os marcadores sanguíneos como AST, ALT, alfa-fetoproteína e APRI (AST-to-platelet ratio índex) constituem fatores preditores do grau de fibrose. Objetivos: Estabelecer o perfil epidemiológico da hepatite C na população estudada; correlacionar e comparar os resultados das diferentes técnicas de biópsia hepática com marcadores séricos indiretos de comprometimento hepático (plaquetas, alfa-fetoproteína, transaminases) e com APRI, avaliando a fidedignidade destes como preditores de gravidade da lesão hepática. Casuística e método: Estudo observacional, retrospectivo, análise de 100 prontuários escolhidos aleatoriamente de pacientes infectados cronicamente pelo VHC. Todos os pacientes haviam sido submetidos ou estavam na vigência de tratamento com interferon associado à ribavirina. Resultados: 61,3% era do sexo masculino e 71,1% do genótipo tipo 1. A maior taxa de resposta virológica sustentada foi no gênero feminino (60,6% x 36,7%).Obteve-se 34,7% biópsias percutâneas às cegas; 27,5% percutâneas guiadas por USG e 37,8% videolaparoscópicas. A biópsia videolaparoscópica demonstrou maior correlação com marcadores e escore de APRI (p<0,05): as médias de F0-F2 e F3-F4 foram, respectivamente, TGO - 46,1 x 106,5; TGP - 67,5 x 123,6; Plaquetas - 223.863 x 160.500; alfafetoproteína - 3,02 x 11,97; e APRI - 0,07 x 0,24 . Conclusão: O APRI apresentou correlação com os graus de fibrose hepática na análise videolaparoscópica, sendo a técnica mais fidedigna.

4.
Rev. AMRIGS ; 52(1): 17-23, jan.-mar. 2008. tab
Article in Portuguese | LILACS | ID: biblio-859511

ABSTRACT

O objetivo deste estudo é estimar a prevalência de diabete melito (DM) em pacientes portadores de hepatite crônica pelo vírus da hepatite C (VHC) e naqueles co-infectados por VHC/HIV. Foram avaliados dois grupos: um com pacientes monoinfectados por VHC e outro com pacientes co-infectados por VHC/HIV. Foram avaliados idade, gênero e cor da pele. Nos monoinfectados foi calculado o índice de massa corporal (IMC). Foram realizados aminotransferases, albumina, bilirrubina total, tempo de protrombina e genotipagem do VHC. A biópsia hepática foi realizada em todos os pacientes. Foram avaliados 135 pacientes monoinfectados, dos quais 30 (22,2%) apresentavam DM, e 117 pacientes co-infectados, sendo 35 (29,9%) com DM (p=0,164). A média geral de idade nos monoinfectados foi de 48,28 ± 9,68 anos, superior ao grupo de co-infectados (40,83 ± 9,01 anos). Na avaliação dos dois grupos houve predomínio do gênero masculino. A maioria dos pacientes apresentava pele de cor branca. Avaliando-se o IMC, observou-se distribuição uniforme, com predomínio de IMC acima de 25 kg/m2, independente da presença de DM. Quando avaliados os exames laboratoriais, observou-se que as aminotransferases foram significativamente mais alteradas naqueles pacientes sem DM. Os demais exames não demonstraram diferenças significativas entre os grupos. Houve maior prevalência de genótipo 2 ou 3, sendo que dentre aqueles co-infectados observou-se correlação entre estes e a presença de DM. Quanto à fibrose, houve predomínio de F3/F4 naqueles com DM. Em conclusão, a prevalência de DM nos pacientes monoinfectados pelo VHC e nos co-infectados por VHC/HIV é alta (AU)


The aim of this study was to estimate the prevalence of Diabeters Mellitus (DM) in chronically HCV infected patients and in those coinfected by HCV/HIV. Two groups were evaluated: one infected with HCV virus and the other with co-infection HCV/HIV. The patients in both groups were evaluated for age, gender and skin color. In the monoinfected group the body mass index (BMI) was calculated. Aminotransferases, albumin, total bilirrubin, protrombin time and HCV genotyping were performed. Liver biopsy was performed in all patients. Thirty (22.2%) of 135 monoinfected patients had DM. DM was observed in 35 (29.9%) of 117 co-infected patients (p=0,164). The age in the monoinfected group was 48.28 ± 9.68 years. It was higher than the co-infected group (40.83 ± 9.01 years). In both groups there was a predominance of males and most patients were white. Regarding BMI it was an uniform distribution and BMI higher than 25 Kg/m2 was more frequent. The aminotransferases were significantly higher in those patients without DM. The other exams did not show significant differences between the groups.There was a higher prevalence of genotype 2 or 3. Among the co-infected a correlation was observed between these genotypes and the presence of DM. Liver biopsy showed a predominance of F3/F4 in those with DM. In conclusion, the prevalence of DM in the HCV monoinfected patients and in those co-infected HCV/HIV is high (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , HIV Infections/epidemiology , Hepatitis C/epidemiology , Diabetes Mellitus/epidemiology , Brazil/epidemiology , HIV Infections/complications , Prevalence , Cross-Sectional Studies , Risk Factors , Hepatitis C/complications , Diabetes Mellitus/etiology
5.
São Paulo; s.n; 2006. 107 p.
Thesis in Portuguese | LILACS | ID: lil-587137

ABSTRACT

A transmissão do VHC vem diminuindo após a implementação de diretrizes de triagem de doadores de sangue e adoção de políticas sociais para reduzir o risco de infecção em UDI, entretanto o VHC ainda constitui um grave problema de saúde pública mundial. Em torno de 10% dos pacientes infectados com VHC não referem exposição a nenhum fator de risco conhecido. Alguns estudos demonstraram a presença de RNA em diferentes secreções, sugerindo a existência de outras rotas de transmissão do VHC. Este estudo teve como objetivo analisar as relações filogenéticas de diferentes regiões genômicas do VHC de cônjuges portadores crônicos e correlacioná-las com sequências de portadores crônicos não relacionados atendidos no mesmo ambulatório. Foram selecionados 18 pacientes (9 casais) com genótipo concordante entre eles e 42 controles (14 de cada genótipo encontrados nos casais). Foram amplificadas e sequenciadas as regiões NS3 (~620nt) e NS5B (~360nt). As sequências foram alinhadas usando o programa Clustal X e Bioedit 6.0.7. A presença do sinal filogenético, nas regiões estudadas, foi analisado através do mapeamento da verossimilhança pelo programa Tree-Puzzle. Os modelos evolucionários foram estimados pelo teste de razão de verossimilhança com o auxílio do programa Modeltest e utilizados para as análises das sequências NS3, NS3+NS5B (TrN+I+G) e NS5B(TrNef+I+G). Foram empregados os métodos de distância com algoritmo de agrupamento de vizinhos e máxima verossimilhança com o algoritmo de rearranjo dos braços, seccionando a árvore em dois pedaços e ligando em outras partes, para a construção das árvores, pelo programa PAUP*4b10. Foram calculados os valores de bootstrap, com 1000 réplicas, para a verificação da sustentação de ramos nas topologias. Nas análises foram incluídas sequências referencia do Genbank de diferentes genótipos...


HCV transmission has decreased with the adoption of universal blood donors screening and social policies to reduce risk of infection in IVDU, but HCV is still a worldwide health problem. The epidemiological route of infection cannot be identified in a significant proportion of patients. Some studies demonstrated the presence of viral RNA in different secretions, suggesting the existence of other routes for HCV transmission. The aim of this study was to evaluate the phylogenetical relationships among sequences from different HCV genomic regions from sexual partners of chronic infected patients when analyzed among themselves and when analyzed conjointly with sequences from virus found in non related chronic infected patients attended in the same clinic. Eighteen individuals (9 couples with stable relationship without other risk factors for HCV infection) and forty-two control patients (fourteen from each genotype found in the couples) were selected. NS3 (~620 nts) and NS5B (~360 nts) regions were amplified and sequenced. Sequences were aligned using clustal X 1.81 and Bioedit 6.0.7. Phylogenetic signal/noise ratio in the data set was investigated with a likelihood mapping analysis with the program TREE-PUZZLE. Evolutionary models were chosen by Hierarchical Likelihood Ratio Test (hLRTs) using Modeltest 3.06 and used for analyze NS3, NS3+NS5B (TrN+I+G) and NS5B (TrNef+I+G) sequences. Distance and maximum-likelihood (ML) phylogenetical analyses were performed with PAUP*4b10 and the trees were constructed with NJ and heuristic search. Tree bisection and reconnection (TBR) algorithm respectively.Robustness of trees was evaluated by analyzing 1000 bootstrap replicates. Genbank reference sequences from different genotypes were included in data analysis...


Subject(s)
Humans , Disease Transmission, Infectious , Genetic Heterogeneity , Genotype , Hepatitis C, Chronic , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL